Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Study to Identify Subjects With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

NCT03955913 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT03955913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03955913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Study to Identify Subjects With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
Lead sponsor
Janssen Research & Development, LLC
Phase
Observational
Overall status
Completed
Start date
August 1, 2019
Completion date
September 19, 2022
Enrollment
3,679 (actual)
Sites
199

Conditions

As the registry lists them; a condition with its own page is linked.

receptors, fibroblast growth factor, urothelial cancer